On this page
Key takeaways
• Preclinical evidence for fisetin skin benefits is genuinely substantial — mouse and cell culture studies show UVB photoprotection, reduced wrinkle formation, collagen preservation, and dermal senescent-cell clearance (1,4).
• No human clinical trial has tested either oral or topical fisetin for skin outcomes. The entire dermatological case rests on preclinical data.
• Topical fisetin bypasses the oral bioavailability ceiling — direct application delivers the compound to skin tissue at concentrations that oral capsules cannot achieve.
• Oral fisetin may benefit skin via systemic senolytic clearance of senescent dermal cells, but plasma concentrations from unformulated capsules likely fall short of the senolytic window (5).
• Commercial topical fisetin formulations vary widely in concentration, vehicle, and stability. No standardised topical product has been validated in a controlled trial.
• Dermal senescent-cell accumulation is a genuine driver of skin ageing (8). The mechanistic case for fisetin in this space is coherent even though human evidence is pending.
Quick answer
Fisetin has substantial preclinical evidence for skin benefits — the 2017 Wu paper showed that topical fisetin reduced UVB-induced erythema, wrinkle formation, and collagen loss in hairless mice through Nrf2 activation and matrix metalloproteinase suppression (1). The broader senolytic story extends to skin because dermal senescent-cell accumulation contributes to skin ageing at a cellular level (8). But no human trial has tested either oral or topical fisetin for skin outcomes, and the plasma concentrations achieved by unformulated oral capsules are likely too low to produce meaningful dermal senolytic effect (5). Topical fisetin, delivered directly to skin, bypasses this bioavailability ceiling but faces its own challenges around formulation stability and skin penetration. This article walks through the mouse evidence, the mechanistic case, and the honest gaps. For the full clinical context, see our complete clinician’s guide.
The mouse UVB story — Wu 2017
The most consequential preclinical fisetin skin paper is Wu and colleagues (Int J Mol Sci, 2017) (1). Hairless mice were exposed to chronic UVB irradiation over 15 weeks with or without topical fisetin application. Three findings anchored the paper.
Reduced erythema and epidermal hyperplasia. UVB-induced acute inflammation was suppressed. Chronic epidermal thickening — a hallmark of photoaged skin — was substantially reduced.
Reduced wrinkle formation and preserved dermal collagen. UVB upregulates matrix metalloproteinases (MMPs) that degrade dermal collagen. Fisetin suppressed this MMP upregulation, preserving collagen content and reducing visible wrinkle formation.
Nrf2 pathway activation. Fisetin activated the Nrf2 antioxidant response pathway, upregulating endogenous antioxidant defences (glutathione, superoxide dismutase). This is a coherent mechanism for UVB photoprotection because oxidative stress is the immediate driver of UVB-induced skin damage.
Pal and colleagues (2015) reported similar findings using different UVB models and characterised the underlying signalling in more detail (4). Together these papers establish a mechanistically coherent preclinical case for topical fisetin as a photoprotective and anti-photoaging intervention.
The dermal senolytic case
Beyond the direct photoprotective story, fisetin’s senolytic identity extends to skin. Dermal fibroblasts — the cells that produce collagen and elastin — accumulate senescence with age, particularly in chronically sun-exposed skin. Senescent fibroblasts secrete SASP factors that break down surrounding collagen and reduce nearby healthy fibroblast function. The 2018 Yousefzadeh paper demonstrated that fisetin selectively clears senescent human cells in tissue explants (2), and dermal fibroblasts are among the cell types that respond.
This creates a mechanistic parallel to the pharmaceutical dermal senolytics being developed by companies like UNITY Biotechnology. If dermal senescent-cell burden drives visible skin ageing — and there is good preclinical evidence that it does (8) — clearing those cells might reasonably slow or reverse aspects of skin ageing. Fisetin’s natural-flavonoid identity makes it a more accessible entry into this space than the prescription-drug equivalents.
Oral vs topical — different interventions, different biology
A common source of consumer confusion. Oral fisetin and topical fisetin are different interventions with different pharmacology, different practical constraints, and different evidence bases.
Oral fisetin for skin
Oral fisetin faces the general bioavailability problem (5). A 500 mg oral capsule produces plasma concentrations well below the in vitro senolytic window, and the fraction of that plasma load reaching dermal tissue is smaller still. For oral fisetin to produce meaningful dermal senolytic effect at supplement doses, it would need to either overcome poor bioavailability (via formulation) or accumulate in skin tissue disproportionately to plasma (which has not been demonstrated in humans). The most likely oral fisetin effects on skin are indirect — general antioxidant and anti-inflammatory activity, modest reductions in systemic inflammation, and possibly small contributions to the overall dietary polyphenol pool.
Topical fisetin for skin
Topical application bypasses the oral bioavailability ceiling entirely. Direct application delivers fisetin to skin at concentrations orders of magnitude above what oral capsules can achieve. This is the reason the preclinical UVB studies used topical application — it is the only way to get pharmacologically meaningful concentrations to dermal tissue with an unformulated compound.
The practical challenges of topical fisetin are formulation-related. Fisetin is poorly water-soluble and yellow-orange in colour — stability, solubility, and cosmetic acceptability all require formulation work. Most commercial topical products dissolve fisetin in ethanol, glycols, or oil-based vehicles at concentrations of 0.1 to 1 percent. Skin penetration depends on the specific vehicle. No standardised topical product has been validated in a controlled human trial.
The 2025 liposomal fisetin skin study
Molagoda 2025 reported that liposome-encapsulated fisetin, tested in senescent human dermal fibroblasts, produced strong SASP suppression (senomorphic effect) rather than senolytic apoptosis (6). For skin specifically, this may actually be desirable — chronic SASP suppression addresses the specific inflammatory-secretome problem that drives senescence-related dermal collagen degradation. Whether the 2025 finding applies to all liposomal fisetin skin products or only to the specific formulation tested is unclear. See our liposomal fisetin article for the broader senolytic-vs-senomorphic story.
Practical guidance for readers
If your skin goal is antioxidant and anti-photoaging support:
• A high-quality broad-spectrum sunscreen is the load-bearing intervention — no supplement or topical antioxidant substitutes for adequate sun protection. All the fisetin data are about supporting existing sun-protection efforts, not replacing them.
• Topical fisetin may add value as an antioxidant serum used alongside sunscreen. Look for products with disclosed concentration (0.1–1%) and an oil or glycol vehicle for better skin penetration.
• Oral fisetin for skin outcomes is speculative at typical supplement doses. If you take oral fisetin for other reasons (senolytic protocol, general polyphenol supplementation), any skin benefit is a bonus rather than a primary rationale.
• Dietary strawberries deliver small quantities of fisetin alongside vitamin C and other antioxidants relevant to skin health. Independent evidence supports the general case for polyphenol-rich diets and skin outcomes.
What we still don't know
• Whether topical fisetin produces measurable clinical benefit on wrinkles, photodamage, or dermal thickness in humans. No RCT has tested this.
• Whether oral fisetin at any dose meaningfully reduces dermal senescent-cell burden in humans. Plasma-to-skin distribution is unmeasured.
• The optimal topical concentration, vehicle, and application frequency for fisetin. No standardised product has been validated.
• Whether liposomal or nanoemulsion topical fisetin outperforms simple oil-based formulations for skin penetration and clinical effect.
• How fisetin interacts with retinoids, vitamin C, or peptide serums in a real skincare routine. Untested.
Bottom line
Fisetin has strong preclinical evidence for skin benefits from mouse UVB studies and cell culture work on dermal senescence. No human clinical trial has tested either oral or topical fisetin for skin outcomes, and the plasma concentrations achieved by unformulated oral capsules are likely too low to produce meaningful dermal effects. Topical fisetin bypasses the bioavailability ceiling but faces formulation and standardisation challenges. The mechanistic case is coherent — dermal senescent-cell accumulation is a genuine driver of skin ageing and fisetin’s senolytic activity is well characterised in mice — but the human clinical translation remains speculative. For serious skin outcomes, sun protection is the load-bearing intervention. Fisetin, in either oral or topical form, is a plausible adjunct with pending evidence. For the complete context, see our complete clinician’s guide and our dedicated senolytic article.
Frequently asked questions
Does fisetin actually help with wrinkles?
Preclinically in mice, yes — topical fisetin reduced UVB-induced wrinkle formation and preserved collagen (1). Human trial data are absent.
Should I take oral fisetin or use topical?
For skin outcomes specifically, topical is more mechanistically direct because oral fisetin’s bioavailability ceiling limits dermal delivery.
Can I make my own topical fisetin?
Technically possible — fisetin powder dissolved in a carrier oil at 0.5–1% — but stability, penetration, and standardisation are hard to achieve at home. Commercial products with disclosed formulation are more predictable.
Does fisetin lighten skin?
No documented depigmenting effect. Fisetin is itself yellow-orange and may cause transient staining of skin at high topical concentrations.
Is topical fisetin safe on sensitive skin?
Generally yes at low concentrations (0.1–0.5%). Patch test before regular use, particularly if you have known flavonoid or polyphenol sensitivity.
References
1. Wu PY, Lyu JL, Liu YJ, et al. Fisetin regulates Nrf2 expression and the inflammation-related signaling pathway to prevent UVB-induced skin damage in hairless mice. Int J Mol Sci. 2017;18(10):2118. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666800/
2. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
3. Adhami VM, Syed DN, Khan N, Mukhtar H. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol. 2012;84(10):1277-1281. https://pubmed.ncbi.nlm.nih.gov/22842628/
4. Pal HC, Athar M, Elmets CA, Afaq F. Fisetin inhibits UVB-induced cutaneous inflammation and activation of PI3K/AKT/NFκB signaling pathways in SKH-1 hairless mice. Photochem Photobiol. 2015;91(1):225-234. https://pubmed.ncbi.nlm.nih.gov/25169110/
5. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72
6. Molagoda IMN, Sanjaya SS, Athapaththu AMGK, et al. Fisetin-loaded liposomes suppress senescence-associated secretory phenotype in senescent human dermal fibroblasts: a shift from senolytic to senomorphic activity. Antioxidants (Basel). 2025;14(7):864. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12347707/
7. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018;14(10):576-590. https://pubmed.ncbi.nlm.nih.gov/30046148/
8. Khosla S, Farr JN, Tchkonia T, Kirkland JL. The role of cellular senescence in ageing and endocrine disease. Nat Rev Endocrinol. 2020;16(5):263-275. https://pubmed.ncbi.nlm.nih.gov/32161396/